National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Trientine tetrahydrochloride (TETA 4HCL) – Cuprior® for the treatment of Wilson’s disease in adults and children ≥ five years intolerant to D-penicillamine therapy.

 

NCPE Assessment Process Complete
Rapid review commissioned 19/08/2019
Rapid review completed 09/10/2019
Rapid Review outcome A full HTA is not recommended.The NCPE recommends that trientine tetrahydrochloride (TETA 4HCl) not be considered for reimbursement at the submitted price

 

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.